PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[−] metastatic breast cancer - Llombart-Cussac, A; Pérez-García, J M; Bellet, M (J Clin Oncol, 2020)